Micromedex Training Center
OVERVIEW
Micromedex® Compendia Resources
Through the process established by the Centers for Medicare and Medicaid Services (CMS), Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:
- Criteria used to evaluate the request (therapy)
- Disclosure of evidence considered
- Meeting minutes and records of votes for disposition of the request (therapy)
- Names of individuals who have substantively participated in the development of the compendia recommendations and disclosure of any potential conflicts of interest
To meet these requirements, documents detailing this information for each drug/off-label use pair published are posted below. A rolling archive of the past seven years of documentation will be maintained and readily accessible.
Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the Micromedex Compendia Uses Policy.
Micromedex® Compendia Policy
This document outlines the policy and procedures employed by Micromedex® Editorial teams to identify clinically relevant off-label uses for FDA-approved medications and develop evidence-based content for inclusion in Micromedex content sets to support the designation of DRUGDEX® as a named compendium for the CMS. 3 pages
Micromedex® Off-label Request Process
This document outlines the process by which external parties may submit a request for a new off-label use to be evaluated for inclusion in Micromedex DRUGDEX®. Any consideration will be done independently by Micromedex editorial staff following existing policies to maintain objectivity and editorial independence. 2 pages
Get to know our capabilities
Explore the Micromedex capabilities and features that provide comprehensive clinical decision support for clinicians at the point of care.
Abemaciclib
Abiraterone Acetate
Acalabrutinib
Acetylcysteine
Ado-Trastuzumab Emtansine
Alemtuzumab
Amitriptyline Hydrochloride
Apixaban
Aspirin
Atezolizumab
Bendamustine Hydrochloride
Bevacizumab
Brentuximab vedotin
Calcium gluconate
Capecitabine
Carfilzomib
Dalteparin
Daratumumab
Eltrombopag Olamine
Eribulin Mesylate
Fam-Trastuzumab Deruxtecan-nxki
Gemcitabine hydrochloride
Ibrutinib
Inotuzumab ozogamicin
Isatuximab-irfc
Ixazomib
Lenalidomide
Magnesium sulfate
Metformin hydrochloride
Minocycline Hydrochloride
Mirtazapine
Nilotinib Hydrochloride
Nivolumab
Ofatumumab
Olanzapine
Olaparib
Paclitaxel Protein-Bound
Palbociclib
Pazopanib Hydrochloride
Pembrolizumab
2020 Malignant mesothelioma of pleura; Previously treated
2020 Triple-negative breast cancer; Early, neoadjuvant, in combination with standard chemotherapy
2021 Renal cell carcinoma; First-line, in combination with lenvatinib
2022 Malignant tumor of anus; Advanced or metastatic squamous cell disease, previously treated
2025 Melanoma, neoadjuvant, resectable, stage III or IV disease
2023 Urothelial carcinoma Adjuvant treatment in those at high risk for recurrence
Polatuzumab Vedotin-piiq
Pomalidomide
Ponatinib Hydrochloride
Ramucirumab
Rituximab
Rivaroxaban
Sonidegib
Sunitinib malate
Temozolomide
Tislelizumab-jsgr
Toripalimab-tpzi
Trametinib Dimethyl Sulfoxide
Trifluridine/Tipiracil
Vemurafenib
Venetoclax
Venlafaxine Hydrochloride
Vismodegib